Cargando…

High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs

Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkert, Sylvia, Schubert, Madline, Olmer, Ruth, Engels, Lena, Radetzki, Silke, Veltman, Mieke, Scholte, Bob J., Zöllner, Janina, Pedemonte, Nicoletta, Galietta, Luis J.V., von Kries, Jens P., Martin, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565754/
https://www.ncbi.nlm.nih.gov/pubmed/31080112
http://dx.doi.org/10.1016/j.stemcr.2019.04.014
_version_ 1783426714743865344
author Merkert, Sylvia
Schubert, Madline
Olmer, Ruth
Engels, Lena
Radetzki, Silke
Veltman, Mieke
Scholte, Bob J.
Zöllner, Janina
Pedemonte, Nicoletta
Galietta, Luis J.V.
von Kries, Jens P.
Martin, Ulrich
author_facet Merkert, Sylvia
Schubert, Madline
Olmer, Ruth
Engels, Lena
Radetzki, Silke
Veltman, Mieke
Scholte, Bob J.
Zöllner, Janina
Pedemonte, Nicoletta
Galietta, Luis J.V.
von Kries, Jens P.
Martin, Ulrich
author_sort Merkert, Sylvia
collection PubMed
description Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the development and conduction of an organotypic HT Cl(−)/I(−) exchange assay using cystic fibrosis (CF) disease-specific iPSCs. The introduction of a halide-sensitive YFP variant enabled automated quantitative measurement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in iPSC-derived intestinal epithelia. CFTR function was partially rescued by treatment with VX-770 and VX-809, and seamless gene correction of the p.Phe508del mutation resulted in full restoration of CFTR function. The identification of a series of validated primary hits that improve the function of p.Phe508del CFTR from a library of ∼42,500 chemical compounds demonstrates that the advantages of complex iPSC-derived culture systems for disease modeling can also be utilized for drug screening in a true HT format.
format Online
Article
Text
id pubmed-6565754
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65657542019-06-20 High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs Merkert, Sylvia Schubert, Madline Olmer, Ruth Engels, Lena Radetzki, Silke Veltman, Mieke Scholte, Bob J. Zöllner, Janina Pedemonte, Nicoletta Galietta, Luis J.V. von Kries, Jens P. Martin, Ulrich Stem Cell Reports Resource Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the development and conduction of an organotypic HT Cl(−)/I(−) exchange assay using cystic fibrosis (CF) disease-specific iPSCs. The introduction of a halide-sensitive YFP variant enabled automated quantitative measurement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in iPSC-derived intestinal epithelia. CFTR function was partially rescued by treatment with VX-770 and VX-809, and seamless gene correction of the p.Phe508del mutation resulted in full restoration of CFTR function. The identification of a series of validated primary hits that improve the function of p.Phe508del CFTR from a library of ∼42,500 chemical compounds demonstrates that the advantages of complex iPSC-derived culture systems for disease modeling can also be utilized for drug screening in a true HT format. Elsevier 2019-05-09 /pmc/articles/PMC6565754/ /pubmed/31080112 http://dx.doi.org/10.1016/j.stemcr.2019.04.014 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Resource
Merkert, Sylvia
Schubert, Madline
Olmer, Ruth
Engels, Lena
Radetzki, Silke
Veltman, Mieke
Scholte, Bob J.
Zöllner, Janina
Pedemonte, Nicoletta
Galietta, Luis J.V.
von Kries, Jens P.
Martin, Ulrich
High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title_full High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title_fullStr High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title_full_unstemmed High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title_short High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
title_sort high-throughput screening for modulators of cftr activity based on genetically engineered cystic fibrosis disease-specific ipscs
topic Resource
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565754/
https://www.ncbi.nlm.nih.gov/pubmed/31080112
http://dx.doi.org/10.1016/j.stemcr.2019.04.014
work_keys_str_mv AT merkertsylvia highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT schubertmadline highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT olmerruth highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT engelslena highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT radetzkisilke highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT veltmanmieke highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT scholtebobj highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT zollnerjanina highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT pedemontenicoletta highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT galiettaluisjv highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT vonkriesjensp highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs
AT martinulrich highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs